Go or no go? Seagen's Padcev eyes FDA approval
Seres and Pfizer are also set for upcoming FDA Pdufa decisions, and a panel is scheduled for Astrazeneca and Merck’s Lynparza.
Unpacking Royalty Pharma
The serial acquirer of royalty interests is coming into its own, but the secret to its success lies in cystic fibrosis.
Theravance gets a fresh start
Meanwhile, Royalty Pharma bets that Trelegy will do better than the sellside expects.
One chance for Glaxo’s triple
The UK company's triple combo just got US approval, and now the group must meet rising analyst expectations.
